Exploring a conundrum: Evaluating the role of neoadjuvant chemotherapy preceding chemo-radiotherapy in locally advanced cervical cancer: A review article

被引：0
作者：
Soni, Sweta [1 ]
Pruthi, Deep Shankar [2 ]
机构：
[1] All India Inst Med Sci, Dept Radiat Oncol, Rajkot, Gujarat, India
[2] Act Canc Hosp, Dept Radiat Oncol, New Delhi, India
来源：
TAIWANESE JOURNAL OF OBSTETRICS & GYNECOLOGY | 2025年 / 64卷 / 02期
关键词：
Uterine cervical Neoplasm; Neoplasm; Chemoradiotherapy; Neoadjuvant therapy; Survival; INDIVIDUAL PATIENT DATA; PHASE-II; CONCURRENT CHEMORADIOTHERAPY; PELVIC RADIATION; PLUS CISPLATIN; OPEN-LABEL; CHEMORADIATION; RADIOTHERAPY; CARCINOMA; STAGE;
D O I：
10.1016/j.tjog.2024.10.013
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
In India, majority of women's with cervical cancer have locally advanced disease. The chemoradiotherapy (CRT) followed by brachytherapy is the standard treatment for patients with locally advanced cervical cancer (LACC) disease for almost decades. But in developing countries like India with higher incidence and limited radiotherapy facilities, this may result in a delay in treatment initiation. These factors may further contribute to detrimental outcomes. Several researchers have tried to study role of neo-adjuvant chemotherapy (NACT) in LACC with the aim that neo-adjuvant chemotherapy may arrest the disease progression, prevent distant metastasis and therefore improve overall and disease-free survival. However, there is only limited literature so far, comparing NACT followed by CRT with the standard treatment arm alone. Therefore the review article aims to evaluate role of neo-adjuvant chemotherapy (NACT) followed by chemo-radiotherapy in LACC. (c) 2025 Taiwan Association of Obstetrics & Gynecology. Publishing services by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码：219 / 229
页数：11
相关论文
共 53 条
  • [1] Bray F., Laversanne M., Sung H., Ferlay J., Siegel R.L., Soerjomataram I., Et al., Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA A Cancer J Clin, 74, 3, pp. 229-263, (2024)
  • [2] Singh D., Vignat J., Lorenzoni V., Eslahi M., Ginsburg O., Lauby-Secretan B., Et al., Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative, Lancet Global Health, 11, 2, pp. e197-e206, (2023)
  • [3] Halperin E.C., Wazer D.E., Perez C.A., Brady L.W., Principles and practice of radiation oncology, Perez and Brady's Principles and practice of radiation oncology, (1934)
  • [4] Pecorelli S., Zigliani L., Odicino F., Revised FIGO staging for carcinoma of the cervix, Int J Gynecol Obstet, 145, pp. 129-135, (2009)
  • [5] Human Papillomavirus (HPV) Vaccines: Q & A. Fact sheets: risk factors and possible causes, pp. 10-22, (2009)
  • [6] Rose P.G., Bundy B.N., Watkins E.B., Thigpen J.T., Deppe G., Maiman M.A., Et al., Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer, N Engl J Med, 340, pp. 1144-1153, (1999)
  • [7] Morris M., Eifel P.J., Lu J., Grigsby P.W., Levenback C., Stevens R.E., Et al., Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer, N Engl J Med, 340, pp. 1137-1143, (1999)
  • [8] Lanciano R., Calkins A., Bundy B.N., Parham G., Lucci J.A., Moore D.H., Et al., Randomized comparison of weekly cisplatin or protracted venous infusion of fluorouracil in combination with pelvic radiation in advanced cervix cancer: a gynecologic oncology group study, J Clin Oncol, 23, 33, pp. 8289-8295, (2005)
  • [9] Martinez A., Angeles M.A., Querleu D., Ferron G., Pomel C., How should we stage and tailor treatment strategy in locally advanced cervical cancer? Imaging versus para-aortic surgical staging, Int J Gynecol Cancer, 30, 9, pp. 1434-1443, (2020)
  • [10] Narayan S., Sharma N., Kapoor A., Sharma R., Kumar N., Singhal M., Et al., Pros and cons of adding of neoadjuvant chemotherapy to standard concurrent chemoradiotherapy in cervical cancer: a regional cancer center experience, J Obstet Gynaecol India, 66, pp. 385-390, (2016)
123456